Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Nabriva Therapeutics plc | a17-8508_1ex32d2.htm |
| EX-32.1 - EX-32.1 - Nabriva Therapeutics plc | a17-8508_1ex32d1.htm |
| EX-31.2 - EX-31.2 - Nabriva Therapeutics plc | a17-8508_1ex31d2.htm |
| EX-31.1 - EX-31.1 - Nabriva Therapeutics plc | a17-8508_1ex31d1.htm |
| EX-21 - EX-21 - Nabriva Therapeutics plc | a17-8508_1ex21.htm |
| 10-K - 10-K - Nabriva Therapeutics plc | a17-8508_110k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-214197) and S-8 (No. 333-208097) of Nabriva Therapeutics AG of our report dated March 24, 2017 relating to the financial statements, which appears in this Form 10-K.
|
/s/ Alexandra Rester |
|
|
|
|
|
Austrian Certified Public Accountant |
|
PwC Wirtschaftsprügung GmbH
Erdbergstrasse 200, 1030 Vienna, Austria
March 24, 2017